VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
RDY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
RDYDr. Reddy's Laboratories Limited
$14.79$12.3B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. RDY
  4. Financial Ratios

Dr. Reddy's Laboratories Limited (RDY) Financial Ratios

Latest Ratios: P/E Ratio 41.1x · EV/EBITDA 23.7x · ROE 12.7%. (2001–2026 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

RDY Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Market Cap$12.3B$11.5B$11.0B$12.2B$9.5B$9.3B$10.2B$6.7B$6.7B$5.4B$6.7B
Enterprise Value$13.0B$72.3B$43.1B$25.1B$17.2B$28.3B$10.4B$7.0B$42.9B$53.5B$37.8B
P/E Ratio →41.100.260.190.220.210.390.590.070.070.110.11
P/S Ratio3.470.030.030.040.040.044.000.040.040.040.05
P/B Ratio3.090.030.030.040.040.054.313.270.050.040.05
P/FCF95.820.360.910.680.241.020.440.280.320.78—
P/OCF20.320.200.240.270.160.330.290.220.230.300.31

P/E links to full P/E history page with 30-year chart

RDY EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
EV / Revenue—0.200.130.090.070.134.080.040.280.380.27
EV / EBITDA23.731.020.480.300.250.680.790.241.302.261.52
EV / EBIT24.801.170.540.340.280.8528.760.241.843.542.47
EV / FCF—2.253.581.400.433.120.450.292.027.66—

RDY Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Gross Margin52.8%52.8%58.5%58.6%56.7%53.1%50.8%53.8%54.2%53.7%55.6%
Operating Margin13.8%13.8%22.1%24.3%23.2%13.7%16.9%9.2%13.6%8.4%9.6%
Net Profit Margin12.8%12.8%17.4%19.9%18.3%11.0%9.1%11.2%12.2%6.9%8.5%

Return on Capital

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
ROE12.7%12.7%18.3%21.8%21.4%24.4%10.5%27.4%14.1%7.8%9.5%
ROA8.5%8.5%12.8%15.7%14.7%15.9%6.9%17.1%8.3%4.4%5.6%
ROIC9.1%9.1%16.3%19.1%19.1%20.8%13.2%13.4%8.9%5.4%7.3%
ROCE12.8%12.8%22.0%25.7%26.3%29.3%18.8%19.1%13.0%8.2%9.7%

RDY Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Debt / Equity0.200.200.140.070.060.180.180.140.270.400.40
Debt / EBITDA1.071.070.530.240.190.820.030.011.162.151.99
Net Debt / Equity—0.160.100.050.030.100.090.130.260.380.25
Net Debt / EBITDA0.860.860.360.160.110.460.020.011.092.031.25
Debt / FCF—1.892.670.720.192.100.010.011.706.88—
Interest Coverage15.6615.6628.1443.0043.2734.710.372114.4126.2519.2024.11

RDY Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Current Ratio1.801.801.922.582.381.931.781.791.921.571.18
Quick Ratio1.351.351.371.921.811.391.231.311.361.160.85
Cash Ratio0.520.520.440.850.720.470.410.350.410.300.21
Asset Turnover—0.620.660.720.760.730.7056.880.680.630.64
Inventory Turnover2.232.231.901.822.191.982.03173.872.102.262.19
Days Sales Outstanding—102.45123.10124.65123.51136.66120.491.71110.63129.01118.56

RDY Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Dividend Yield0.6%60.7%60.5%54.4%52.5%44.7%40.6%58.4%59.5%73.5%50.6%
Payout Ratio15.5%15.5%11.8%11.9%11.0%17.6%1785.9%20.1%21.3%40.7%28.2%

Total Shareholder Return Metrics

MetricTTMFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Earnings Yield2.4%389.3%513.8%455.4%475.6%254.2%168.8%1454.8%1396.2%902.3%897.8%
FCF Yield1.0%278.2%109.3%147.2%422.2%97.7%226.6%354.0%315.2%128.6%—
Buyback Yield0.0%0.0%12.6%0.0%0.0%0.0%11.7%7.1%7.9%0.0%100.0%
Total Shareholder Yield0.6%60.7%73.2%54.4%52.5%44.7%52.3%65.5%67.4%73.5%100.0%
Shares Outstanding—$833M$834M$834M$832M$832M$832M$830M$831M$831M$835M

Key Metrics

Growth RegimeDecelerating
ProfitabilityStrained
Balance SheetMixed
Cash FlowDeteriorating
Top Statement Risk

Gross margin erosion accelerating return decay

Gross Margin Erosion Compounds Through Operating Leverage

According to reported financial statements, RDY's operating margin collapsed from 23.4% to 13.7% over ten quarters, compressing roughly 970 basis points as fixed commercial infrastructure failed to scale down with declining gross profit, suggesting structural negative operating leverage is now embedded in the cost base.

The gross margin trajectory from 60.4% in 2025Q1 to 52.1% in 2027Q2 reflects a mix shift toward commoditized formulations and intensified US pricing pressure that the PSAI vertical integration has not fully offset. The operating margin decline of approximately 970 basis points versus only 830 basis points of gross margin compression indicates that SG&A has remained sticky — consistent with the prior income statement finding of $27-29B in SG&A against a shrinking gross profit pool. Net margin compression to 10.7% from 18.1% suggests that below-the-line items, including volatile non-operating charges, are amplifying the operational deterioration rather than cushioning it.

Return on Invested Capital in Steady Decay

As reported in financial statements, RDY's ROIC has halved from 4.4% in 2025Q1 to 2.0% in 2027Q2, while ROE declined from 4.8% to 2.4%, indicating the company is destroying rather than compounding returns on an expanding asset base that grew 39% to $577B over the same period.

The simultaneous decline in both ROE and ROIC — despite leverage increasing from 0.10 to 0.19 debt-to-equity — rules out financial engineering as a mitigating factor and confirms that operating returns are the binding constraint. With ROIC at 2.0% likely below RDY's implied cost of capital (evidenced by the PEG of 1.10 suggesting mid-teens earnings growth expectations), the capital deployed into the 2025 acquisition (goodwill revaluation from $4.2B to $11.8B) and 44% net PPE expansion may not generate adequate risk-adjusted returns. Investors should monitor whether biosimilar and complex generic launches can reaccelerate ROIC toward its 2025 peak, as failure to do so would suggest the acquisition-driven asset expansion is permanently dilutive.

Working Capital Lock-Up Deteriorates Asset Velocity

Based on reported operating metrics, RDY's asset turnover fell from 0.19 to 0.15 over ten quarters while the cash conversion cycle expanded to 218 days in 2027Q2, reflecting a structurally elevated inventory position of 180 days that is absorbing working capital without corresponding revenue velocity.

The DSO trend from 105 to 120 days suggests lengthening receivable collection periods, potentially driven by chargeback-heavy US wholesaler arrangements or slower collections in the Russia/CIS region, which the prior cash flow analysis identified as a source of working capital consumption. Inventory at 180 days of inventory outstanding — while somewhat improved from the 200-day peak in 2025Q2 — remains elevated and aligns with the documented working capital drain of $21.9B across 2027Q1 and 2027Q2. The 218-day CCC, roughly 13 days longer than the 2025Q2 trough of 206 days, means each dollar of revenue is tied up in the operating cycle for over seven months, creating a structural drag on cash conversion that explains the volatile and occasionally negative FCF margins.

Debt Build-Out Outpaces Cash Flow Capacity

As disclosed in balance sheet filings, RDY's debt-to-equity ratio rose from 0.10 to 0.19 while interest coverage fell from 31.57x to 9.53x, with D/EBITDA spiking to 24.21x in 2027Q1, indicating that the debt-funded acquisition strategy has meaningfully eroded the company's once-fortress-like debt service cushion.

While a 0.19 debt-to-equity ratio remains modest in absolute terms for a specialty pharmaceutical manufacturer, the trajectory is the material concern: total debt more than doubled to $72.6B against a backdrop of operating cash flow that turned negative in 2027Q1. The 2027Q1 D/EBITDA spike of 24.21x appears to reflect a temporary EBITDA trough rather than a permanent solvency issue, as 2027Q2 coverage recovered to 4.24x D/EBITDA and 9.53x interest coverage. However, if margin compression continues and goodwill impairment risk crystallizes against the $13.0B carrying value, the company's leverage profile could deteriorate more rapidly than headline ratios suggest. Refinancing risk appears minimal given the modest absolute leverage, but the pattern warrants monitoring for further debt-funded capital allocation.

P/E Misapplied to Non-Recurring Gain-Laden Earnings

The trailing P/E of 23.26 is the most commonly misapplied ratio for RDY because volatile one-time litigation settlements, brand divestment gains, and inconsistent stock-based compensation accruals distort reported EPS, making the multiple appear richer than underlying operational earning power would justify on a normalized basis.

For a specialty generic manufacturer like RDY, where Paragraph IV litigation settlements and non-core divestitures regularly inject lump-sum gains into the P&L, the trailing P/E ratio systematically conflates one-time cash inflections with recurring operating earnings. The prior income statement analysis documented EPS declining 86% in 2026Q4 while non-operating items including SBC swings from $0 to $113M further distort the bottom line. A more appropriate metric would be EV/EBITDA adjusted for non-recurring items — the reported 15.66x EV/EBITDA provides a cleaner read — or a mid-cycle P/E applied to normalized margins. With cumulative 10-quarter OCF/NI at approximately 0.79, a P/E-based valuation framework overstates RDY's true earnings power by roughly 20% relative to cash generation, meaning the apparently modest forward multiples may not reflect the operational reality investors are underwriting.

Download Financial Ratios Data

Includes 30+ ratios · 26 years · Updated daily

Consensus & Technical Research Suite
Open RDY Terminal

RDY Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

RDY — Frequently Asked Questions

Quick answers to the most common questions about buying RDY stock.

What is Dr. Reddy's Laboratories Limited's P/E ratio?

Dr. Reddy's Laboratories Limited's current P/E ratio is 41.1x. The historical average is 0.2x. This places it at the 100th percentile of its historical range.

What is Dr. Reddy's Laboratories Limited's EV/EBITDA?

Dr. Reddy's Laboratories Limited's current EV/EBITDA is 23.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 2.6x.

What is Dr. Reddy's Laboratories Limited's ROE?

Dr. Reddy's Laboratories Limited's return on equity (ROE) is 12.7%. The historical average is 15.5%.

Is RDY stock overvalued?

Based on historical data, Dr. Reddy's Laboratories Limited is trading at a P/E of 41.1x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What is Dr. Reddy's Laboratories Limited's dividend yield?

Dr. Reddy's Laboratories Limited's current dividend yield is 0.61% with a payout ratio of 15.5%.

What are Dr. Reddy's Laboratories Limited's profit margins?

Dr. Reddy's Laboratories Limited has 52.8% gross margin and 13.8% operating margin. Operating margin between 10-20% is typical for established companies.

How much debt does Dr. Reddy's Laboratories Limited have?

Dr. Reddy's Laboratories Limited's Debt/EBITDA ratio is 1.1x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.